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Transcriptional pharmacology of neurodegenerative
disorders: novel venue towards neuroprotection against
excitotoxicity?
Transcription factors NF-kB/Rel represent the point of convergence of several signalling path-
ways relevant to neurodegeneration. The finding that salicylates elicit neuroprotection via
blockade of NF-kB provides new opportunities for pharmacological intervention.
The term neurodegenerative as applied to diseases of has allowed us to reach down to the nuclear parti-
cipants of the glutamate-evoked cell death programthe nervous system is used to designate a group of
disorders in which there is gradual, generally including transcription factors and their targeted
genes.3 Among the transcription factors that are acti-symmetric, relentlessly progressive wasting away of
neurons for reasons still unknown. A striking feature vated by glutamate in neuronal cells, there are proteins
belonging to the NF-kB/Rel family.4 Recent work sug-of a number of disorders of this class is the almost
selective involvement of anatomically and physiologi- gests a pivotal role of these regulatory proteins along
the glutamate-evoked cascade of events leading to cellcally related subgroups of neurons. The abnormal loss
of neurons that may occur during development or as a death since blockade of their activation can result in
effective neuroprotection.5result of an injury represents the functional substrate
of many symptoms easily detectable in a number of Until recently, the properties of NF-kB/Rel proteins
have been most extensively exploited in cells of theneurological and psychiatric disorders. The under-
standing of the mechanisms that account for specific immune system or, more in general, in periphery,
where these regulators are implicated in the transcrip-neuronal dysfunction and death in these diseases rep-
resents a major challenge for both clinical and basic tional control of genes involved in inflammatory,
immune, and acute phase responses.4 Some recentneuroscientists.
In the last years dysfunction of the ionotropic gluta- reports have suggested that NF-kB/Rel proteins are
likely to participate in normal and pathological brainmate-activated neurotransmitter receptors, which are
the principal providers of fast neurotransmission in function.6–8 Despite these important contributions,
very little is known on the CNS genes whosemammalian brain, has been extensively implicated
since excessive or persistent activation of these recep- expression is under NF-kB control. We recently found
that two major pathogenic pathways which are likelytors results in neuronal death by excitotoxicity.1 Brain
damage through excitotoxicity has been closely asso- to contribute to the neuropathology associated with
Alzheimer’s disease, namely the inflammatory cyto-ciated with acute conditions like stroke, trauma,
ischaemia, hypoglycemia, but also with epilepsy and kine IL-1b and glutamate, can contribute to NF-kB
induction.9–10 We also tested whether anti-inflamma-ALS. A contribution of excitotoxicity to chronic and
progressive neuropathologies like Alzheimer’s and Par- tory drugs, and aspirin in particular, may prevent glut-
amate-induced NF-kB activation in neuronal cells.kinson’s diseases has also been suggested.2
Interference with glutamate receptor function has Why aspirin? There are several reasons that made these
drugs extremely interesting from our point of view.been extensively explored as a means to develop com-
pounds able to attenuate or prevent excitotoxicity. First, clinical and experimental evidence has suggested
that inflammation may be a common component ofMore recently, the search for novel targets for pharma-
cological manipulation of excitotoxicity has been several neurodegenerative conditions, in particular of
AD (reviewed by McGeer11). Various inflammatorydirected towards the intracellular events triggered by
neurotoxic concentrations of glutamate. This approach cells (activated microglia) and mediators (cytokines,
complement factors, acute phase reactants) are com-
monly found closely associated to plaques or degener-
ating neurons. Second, several retrospective epidemio-Correspondence: Dr M Memo, Section of Pharmacology, Depart-
logical studies showed a lower incidence ofment of Biomedical Science and Biotechnologies, University of
Brescia, Medical School, Via Valsabbina 19, 25123 Brescia, Italy Alzheimer’s disease in patients who received chronic
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anti-inflammatory therapy for treatment of rheumatoid erative disorders has still to be evaluated but it could
be of great relevance. These molecules would appeararthritis.11 In a small clinical trial, indomethacin has
demonstrated some efficacy in slowing down pro- to possess a wider pharmacological spectrum com-
pared to other NSAID. In view of their dual and dis-gression in people affected by AD.12 Finally, Kopp and
Gosh13 showed that salicylates are endowed with the tinct ability of acting not merely as anti-inflammatory
compounds but also directly as antidegenerative mol-ability to block NF-kB activation. This mechanism has
been purported to be highly contributory to the ecules, we would predict a potential great benefit from
the employment of aspirin-derived drugs in neurodeg-pharmacological properties of these drugs since the key
role of NF-kB proteins is controlling immune and enerative processes. Furthermore these results may
open up interesting perspectives in the development ofinflammatory function.
Under these exciting premises, we tested whether, at novel strategies for therapeutic intervention in neuro-
degenerative states, namely a transcriptional pharma-concentrations compatible with plasma levels reached
during treatment of chronic inflammatory states, cological approach.
aspirin and sodium salicylate may interfere with gluta-
mate-induced activation of NF-kB and cell death. Both M Grilli and M Memo
Section of Pharmacologydrugs turned out to be effectively neuroprotective. Sur-
prisingly, the neuroprotective effect did not appear to Dept Biomedical Sciences and Biotechnologies
University of Brescia, Medical Schoolcorrelate with the anti-inflammatory properties of this
compound since: (i) indomethacin was inactive; (ii) in Via Valsabbina 19, 25123 Brescia, Italy
our experimental settings, aspirin was equi- or more
potent than its metabolite salicylic acid. The molecular
target for aspirin and sodium salicylate to exert neuro-
protection appeared to be localized downstream of the References
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